Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Dec 16;20(1):2.
doi: 10.1007/s11899-024-00745-8.

Monoclonal Gammopathy-Associated Neuropathy

Shayna Sarosiek  1   2 , Christopher T Doughty  3   4 , Jorge J Castillo  5   4
Affiliations
Review

Monoclonal Gammopathy-Associated Neuropathy

Shayna Sarosiek et al. Curr Hematol Malig Rep. .

Abstract

Purpose of review: Peripheral neuropathy (PN) is more commonly seen in individuals with monoclonal gammopathies, especially in patients with an IgM monoclonal gammopathy or Waldenström macroglobulinemia.

Recent findings: There are multiple potential ways that the paraprotein may result in peripheral neuropathy. The diagnosis and management of monoclonal gammopathy-associated PN are challenging and necessitate a concerted effort between the hematologist/oncologist and the neurologist. This review describes the most common PN syndromes associated with monoclonal gammopathy, such as anti-myelin-associated glycoprotein neuropathy, light chain amyloidosis, cryoglobulinemia, POEMS, CANOMAD, and others. We also review the therapies used to treat these conditions.

Keywords: Amyloidosis; Anti-MAG; CANOMAD; Cryoglobulinemia; Monoclonal gammopathy; Neuropathy; POEMS; Waldenström macroglobulinemia.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of Interest: SS received research funds or honoraria from Beigene, Cellectar, and ADC Therapeutics. CTD received research funds from AstraZeneca and honoraria from Argenx, UCB, and TD Cowen. JJC received research funds or honoraria from Abbvie, AstraZeneca, Beigene, Cellectar, Janssen, Kite, Loxo, and Pharmacyclics. Human and Animal Rights and Informed Consent: This article does not contain any studies with human or animal subjects performed by any of the authors.

References

    1. Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Offord JR, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006;354(13):1362–9. https://doi.org/10.1056/NEJMoa054494 . - DOI - PubMed
    1. Kyle RA, Rajkumar SV. Monoclonal gammopathy of undetermined significance. Br J Haematol. 2006;134(6):573–89. https://doi.org/10.1111/j.1365-2141.2006.06235.x . - DOI - PubMed
    1. Kyle RA, Therneau TM, Rajkumar SV, Offord JR, Larson DR, Plevak MF, et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346(8):564–9. https://doi.org/10.1056/NEJMoa01133202 . - DOI - PubMed
    1. Fermand JP, Bridoux F, Dispenzieri A, Jaccard A, Kyle RA, Leung N, et al. Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications. Blood. 2018;132(14):1478–85. https://doi.org/10.1182/blood-2018-04-839480 . - DOI - PubMed
    1. Hanewinckel R, van Oijen M, Ikram MA, van Doorn PA. The epidemiology and risk factors of chronic polyneuropathy. Eur J Epidemiol. 2016;31(1):5–20. https://doi.org/10.1007/s10654-015-0094-6 . - DOI - PubMed

MeSH terms

LinkOut - more resources